Sherif Makar, MD

Sherif Makar, MD

Neuro-Oncologist

Cancer

Dr. Makar

Overview

Sherif Makar, MD, fellowship-trained neuro-oncologist, received his medical degree from the University of South Florida Morsani College of Medicine in Tampa. He completed his residency training in neurology at the University of Florida College of Medicine in Jacksonville, where he was named Outstanding Resident Educator. Dr. Makar also completed a fellowship in the prestigious Neuro-Oncology program at Stanford University. His primary goal is to provide exceptional care for his patients through research and clinical expertise. Dr. Makar is a member of the Stanford Society of Physician Scholars, the Society of Neuro-Oncology and the American Academy of Neurology.

Articles

Successful Intrathecal Rituximab Administration in Refractory Nonteratoma Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report

JOURNAL OF NEUROSCIENCE NURSING

2019

Oligodendrogliomas-Atypical clinical presentations

OLIGODENDROGLIOMA: CLINICAL PRESENTATION, PATHOLOGY, MOLECULAR BIOLOGY, IMAGING, AND TREATMENT

2019

More Publication Information

Education & Training

Education

University of South Florida Morsani College of Medicine, Tampa, FL

Residency

University of Florida College of Medicine, Jacksonville, FL

Fellowship

Stanford University Medical Center, Stanford, CA

Specialty

Medical Oncology

Board Certifications

American Board of Psychiatry and Neurology

Associated Clinical Trials

NCT05685004

Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).

Icon for trial | TVI AST 008 Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltrans

This study is currently enrolling.

This clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and effective TVI-Brain-1 would be a ...